

Available online on 15.07.2018 at jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

Overview on Chemokine Co-Receptor-5 (CCR-5) HIV-1 Entry Inhibitors

Pant Kavita*, Singh Anita

Department of Pharmaceutical Sciences, Kumaun University Campus Bhimtal, Nainital-263136, Uttarakhand, India

ABSTRACT

In the 21st century, HIV-1 has turned into a noteworthy global challenge in medication. As per WHO report 2017, HIV is one of the deadliest diseases adding to an aggregate of 36.7 million contaminations until December 2016 among which 1.8 million were analyzed in 2016 itself. In 2016, 19.5 million individuals experienced to anti-retroviral treatment summing up to US\$ 11 billion. With regards to rising resistance from anti-retroviral medication in HIV treatment, the advancement of most recent medication classes with a newer mode of action stays essential. The CCR5 co-receptor inhibitors suppress the fusion of HIV with the host cell by upsetting the connection of gp-120 protein with the CCR5 receptor. Though several CCR5 antagonists are assessed in clinical trials, just Maraviroc has been endorsed for clinical use in the treatment of HIV infected patients. The efficacy and safety profile of CCR5 adversaries with a consideration on maraviroc are assessed here in conjunction with their use in newer and developing clinical trials. In the beginning time of HIV-1 infection in the most of patients, the HIV utilizes CCR5 receptor for passage in CD4 cell of the host (CCR5-tropic infection). Maraviroc did not decrease virus load (compared to optimized background therapy) in patients with CXCR4 or dual-tropic virus. Before prescribing a CCR5 blocker HIV tropism testing is recommended. Viral tropism is defined as the capability of the viruses to enter as well as infect the host cell, and it is based on the binding capacity of the viruses to receptors on those host cells. The co-receptor type should be recognized before the treatment started with a CCR5 blocker.

Keywords: CCR5, CXCR4, HIV-1, CD4 cell, Tropism, CYP3A4.

Article Info: Received 21 May, 2018; Review Completed 09 July 2018; Accepted 10 July 2018; Available online 15 July 2018



Cite this article as:

Kavita P, Anita S, Overview on Chemokine Co-Receptor-5 (CCR-5) HIV-1 Entry Inhibitors, Journal of Drug Delivery and Therapeutics. 2018; 8(4):73-79 DOI: <http://dx.doi.org/10.22270/jddt.v8i4.1794>

*Address for Correspondence:

Pant Kavita, Department of Pharmaceutical Sciences, Kumaun University Campus Bhimtal, Nainital-263136, Uttarakhand, India

INTRODUCTION

In the 21st century, HIV-1 has turned into a noteworthy global challenge in medication. As per WHO report 2017, HIV is one of the deadliest diseases adding to an aggregate of 36.7 million contaminations until December 2016 among which 1.8 million were analyzed in 2016 itself. In 2016, 19.5 million individuals experienced to anti-retroviral treatment summing up to US\$ 11 billion. In between 2000 and 2016, new HIV infections fell by 39%, and HIV-related demises reduced by 33% with 13.1 million lives spared due to ART in an exceedingly similar period¹. In AIDS the system becomes compromised and is unable to fight infections^{2,3}. Due to resistance to many antiretroviral drugs, development of new classes of drugs with a new mode of action is essential. The main productive route for HIV treatment is HAART. It is a mix of different

antiretroviral drugs (turn around transcriptase inhibitors, protease inhibitors, integrase inhibitors, co-receptor inhibitors and combination inhibitors). In contrast with different classes, the CCR5 inhibitor is a novel class of HIV-1 inhibitors for HIV-1 treatment approved in recent years. Disclosure of common ligands of CCR5-macrophage inflammatory protein1- α (MIP1- α), RANTES (Regulated upon initiation, Normal T-cell communicated and discharged), and macrophage inflammatory protein1- β (MIP1- β) - as inhibitors quickly discover a method for examine for manufactured ligands to repress the HIV-1 receptor and hinders the viral entry to the cell⁴. The CCR5 receptor is a major co-receptor for viral entry in the host cell, and it is a class of G-protein coupled receptor family having an essential role in the R5- tropic HIV-1 entry.

DEVELOPMENT STAGES

Till now few CCR5 inhibitors are investigated for AIDS treatment. In August 2007 USFDA approve the only drug Maraviroc (Selzentry). Aplaviroc trial was discontinued because of its hepatotoxicity found during clinical trials⁵. INCB009471 an oral antagonist of the CCR5 receptor with prolonged half-life was studied for phase I and II in 2007, but the trials were discontinued by the company. Another drug Vicriviroc was in phase III clinical trial^{6, 7} and halted. Anibamine, the first natural product obtained from *Aniba spp.*, contains quaternary pyridine alkaloids that are potent CCR5 inhibitors⁸. Recently, there are two new potent CCR5 inhibitors discovered by Takeda (TAK-651 and TAK-220). TAK-652 reported to be a potent inhibitor of CCR5 in preclinical trials and is under phase I pharmacokinetic studies. Promising results of TAK-220 has been found in preclinical stages⁹.

ROLE OF CCR5 IN HIV/AIDS

For HIV-1 to enter into a host cell, binding with the CD4 envelope receptor is essential. When HIV-1 binds to the CD4 receptor conformational changes occur in gp120 and the CCR5 binding site is exposed. By this process second conformational change produces in gp41 protein of HIV-1, resulting in fusion of two membranes and viral entry into host cell. Interestingly, Caucasians (1%) in their CCR5 gene has a deletion of homozygous 32 base pairs. In Caucasian individuals expression of CCR5 on the cell surface of CD4 is absent which gives protection against acquiring HIV-1 infection¹⁰. Two main approaches for blocking the entry mechanism of virus entry to host cell is either by interference with protein that binds to CCR5 or by removing the CCR5 from cell surface through carboxy terminus phosphorylation of CCR5.

WHY TROPISM ASSAY IS REQUIRED?

In the early stage of HIV-1 disease in the majority of patients, the virus uses CCR5 receptor for entry in CD4 cell of the host (CCR5-tropic virus). In cases of advanced immuno-suppression around one-half of viral strains enters either through CXCR4 receptor alone, or

both CXCR4 and CCR5 receptors (R4 or dual-tropic). About 80% of the HIV-naïve patients are infected with the R5 tropic virus, while approximately 50% of the pretreated patients of the HIV-1 are exclusively infected with CCR5 viral strains. For patients, solely infected with CCR5 tropic viral strains maraviroc has been approved. Maraviroc did not decrease virus load (compared to optimized background therapy) in patients with CXCR4 or dual-tropic virus¹¹.

European guidelines for the tropism assay

Viral tropism is defined as the capability of the viruses to enter as well as infect the host cell, and it is based on the binding capacity of the viruses to receptors on those host cells. Before prescribing a CCR5 blocker HIV tropism testing is recommended. The co-receptor type should be recognized before the treatment started with a CCR5 blocker¹². Tropism testing is powerfully suggested in all patients who have medicine failure for whom a CCR5 antagonist is being thought about as a part of the following programme. Tropism testing is moderately counseled altogether patients for whom treatment has did not give insight into future treatment choices. Patients showing adverse events along with its current regimen or unexplained neurological pathology, treatment containing CCR5 co-receptor inhibitors will be of potential worth. In patients who have been diagnosed recently, the role of tropism assay as an indicator for future use of CCR5 antagonist or as a prognostic marker is not sufficiently illustrious to justify any recommendation¹³. In antiviral-naïve patients at high risk of hepatotoxic and neurological abnormalities of first-line treatment, CCR5-tropism testing could be done before initiating any therapy so, if toxic effects develop, a procedure will be changed to include CCR5 antagonists without further tests. Samples ought to be collected as close as possible to the time of beginning treatment. The utilization of maraviroc in HIV-naïve patients is not approved by the European Medicines Agency¹². Tropism is often assessed with either genotypic or phenotypic technique.

Table1: Some critical methodological characteristics of several phenotypic recombinant method trends within the last years to assess HIV tropism.

Name of the Phenotypic recombinant way	Key methodological characteristics			
	vector Construction	Report gene	Virus Stocks	Sensitivity
XtrackC/PhenX-R In Pheno AG	Clonal technology	β-galactosidase	Defective Replication	1%
Virco NH2-V4 gp120	Recombination	green fluorescent protein	Competent Replication	5-10%
Monogram Biosciences ESTATrofileTM4	Clonal Technology	Luciferase	Defective Replication	0.3-1%
Univ. Toulouse Toulouse Tropism Test (TTT)	Recombination	Luciferase	Competent Replication	0.5%
ISCIH-FISPE Tropitest	Clonal Technology	Luciferase	Competent Replication	1%
VIRalliance Phenoscript	Recombination	β-galactosidase	Competent Replication	5-10%

Phenotypic Assay

The phenotype assays are ordinarily based entirely on recombinant virus's technology. Briefly, the gene is amplified with the aid of PCR (Polymerase Chain Reaction) from plasma samples. In the end, recombinant virions are generated through genetic or clonal recombination. The recombinant virus debris is used to infect cell lines expressing the CD4 receptor and both CCR5 or CXCR4. The phenotypic assay Trofile™ has been appreciably used to provide tropism knowledge in the maraviroc trials, and hence it's been the most extensively used up to now¹³⁻¹⁵.

Genotypic Assay

Genotypic assays constitute an extra viable opportunity to phenotypic assays for the reason that they're speedier, less expensive, and extensively to be had among laboratories that specialize in HIV diagnosis. During the early 1990s, numerous rules, and algorithms had been developed to expect HIV co-receptor usage based entirely on V3 sequences, lots of them at the moment are free to be had through publicly accessible websites. The "11/25 rule" was the earliest algorithm advanced for viral tropism interpretation and remained one of the most famous till current times. It's far primarily based on the truth that viruses offering essential amino acids such as arginine (R) or lysine (k) at positions 11 and 25 are regularly related to an X4-tropic phenotype. Conversely, non-existence of R or K in those areas is related to R5-tropic viruses¹⁶. Despite the fact that this rule shows high specificity (80-90%), it can be afflicted by low sensitivity (30-40%) in figuring out X4-tropic viruses in contrast with phenotypic assays. Currently, a modification of the 11/25 rule has been proposed that improves the predictive cost for viral tropism. It is

regarded as the 11/24/25 rule and considers variants as X4-tropic when a position 11, 24, or 25 harbours any essential amino acid; otherwise the virus is classed as R5-tropic¹⁷.

The "net charge rule" is a simple interpretation technique that estimates the global net cost of the V3 region in keeping with the following formula:

$$(k+R) - (\text{aspartic acid [D]} + \text{glutamic acid [E]}).$$

If the end result is ≥ 5 , the virus is assessed as X4-tropic; in any other case, it is miles R5- tropic. There is another rule for calculating the net charge that consists of the primary amino acid histidine (H); this is as follows:

$$(k+R+H) - (D+E).$$

But, this alternative approach is much less correct than the guideline that does not include H (79 vs 49%). Similar to the 11/25 rule, the net charge rule indicates excessive specificity but suffers from low sensitivity in figuring out X4 variants^{18, 19}. During the last decade, efforts have been made to discover residues in the V3 area which can be involved in determining viral tropism. The natural variability of the V3 location has been examined in a couple of HIV isolates phenotypically categorized as R5- and X4-tropic. Consequently, new residues and particular patterns of amino acids have been recognized as influencing viral tropism. No one trade appears to be responsible for the tropism; as a substitute, numerous clusters of genotypes seem in large part decide viral tropism^{20, 21}. Many algorithms are free to be had on websites such as Wetcat, Geno2phenoreceptor, net PSSM, and Fortinbras PSSM.

Table 2: Some critical methodological characteristics of several genotypic recombinant methods trends within the last years to assess HIV tropism

Name of the Genotypic Methodology	Key methodological characteristics		
	Principle	Sensitivity	Specificity
11/25 rule	R or K at position 11/or 25 is related to an X4-tropic makeup	59.5%	93.4%
11/24/25 rule	R or K at positions 11, 24, or 25 is related to X4-tropic makeup	-	-
Net charge	$K+R - (D+E) \geq 5$ is associated with an X4-tropic makeup	Low	High
Wetcat	HIV tropism predictions measure inferred from genotypic/ makeup paired dataset using applied statistical ways.	22%	90%
Geno2pheno	These algorithms for HIV tropism interpretation square measure freely obtainable on websites.	50%	90%
WebPSSM	-	84%	96%

CLINICAL EFFICIENCY OF CCR5 INHIBITORS

Clinical efficiency of Maraviroc

As Maraviroc is only active against R-5 tropic virus and not against CXCR4 or dual-tropic virus. The maraviroc potency of the HIV-1 virus was studied during the 10-day phase I trial of monotherapy in 63 patients which were previously reported with R-5 tropism. Randomized allocation of patients to treatment with maraviroc 25mg, 100mg, 300mg once daily (QD) or 50mg, 100mg, 150mg twice daily(bid) or placebo for ten days was

done. On day 11, mean decrease of viral copies were found to be more in patients treated with maraviroc in comparison to placebo. No difference was reported in the reduction of viral copies in patients who were fasted vs fed individuals²². In phase II maraviroc efficacy was also determined in patients pretreated with mixed CXCR4 and R5 tropic virus. In maraviroc treated patients the CD4 cell count was shown to be increased, with a change in CD4 cells/mm³ +36, +62, and +60 in placebo group, 150mg (bid) and 150mg (QD) maraviroc respectively¹¹. Further maraviroc is studied for phaseIII trials, in exclusively pretreated HIV-1 patients. In 2007,

maraviroc was being evaluated in phase III studies MOTIVATE-1 (the USA and Canada) and MOTIVATE-2 (Europe, Australia, and the USA) in previously treated and ART-naïve subjects in the study of Pfizer. Maraviroc approved by USFDA in 2007 for pretreated patients²³.

Table 3: Efficacy of maraviroc in trials²²

Doses of the Drug	Mean changes in viral load log ₁₀ copies/ ml ranges at day 11
25mg QD	-0.03
100mg QD	-1.43
300mg QD	-1.35
50mg bid	-0.66
100mg bid	-1.42
150mg bid(fed)	-1.34

Clinical efficiency of Vicriviroc

A 14 days phase I monotherapy study in 48 HIV-naïve patients were studied. The patients were treated with 10mg, 25mg, and 50mg bid for 14 days in a randomized design. Decrease in viral copies were dose-related and the mean log₁₀ c/ml drop of -1.62(50mg bid), -1.56(25mg bid) and -1.08(10mg bid)^{24, 25}. In phase II study is also performed in 92 treatment naïve patients, but the study was terminated due to early virologic breakthrough²⁶. The patients are divided into randomized groups to receive vicriviroc with doses of 25mg, 50mg, 75mg once daily and placebo (efavirenz) for 14 days against the AZT/3TC background. After two weeks the treatment provides promising results. Duration of this study was 48 weeks, but at 32 weeks this study was terminated due to early viral breakthrough.

A double-blind, randomized trial was studied for phase II in 118 patients who experienced the viral breakthrough. In this study, patients received 5mg, 10mg, and 15mg vicriviroc as an add-on to the failing ritonavir containing HAART. Background treatment was optimized after 14 days of treatment. Study with 5mg vicriviroc dose was discontinued due to high virologic failure^{27, 28, 29}. An extended follow-up study for phase II for higher doses gives promising results. In 70% patients the mean viral load declines with <50 copies/ml at 24th week and continued to have <50 copies/ml at week 48³⁰. Vicriviroc was halted in phase III clinical trials because of increased liver malignancies³¹.

Table 4: Efficacy of vicriviroc in trials²⁴

Dose(QD)	Mean changes in viral load log ₁₀ copies/ ml ranges at day 15
10mg	-1.08
25mg	-1.56
50mg	-1.62

Clinical efficiency of Amlaviroc

Amlaviroc also a CCR5 inhibitor and promising results are shown in phase I and IIa study. A decrease was observed in viral load in 0% of the placebo group when

compared with 17% of patients receiving 200mg amlaviroc QD, 200 mg amlaviroc bid received by 75% of patients, 63% of those treated with 400 mg amlaviroc QD and 100% of the patients who were receiving 600 mg amlaviroc bid after 10 days of treatment³². However, phase IIb and III trials were discontinued because of hepatotoxicity³³.

Table 5: Efficacy of amlaviroc in trials³²

Doses	Mean changes in viral load log ₁₀ copies/ ml ranges at day 11
200mg QD	-0.46
200mg bid	-1.23
400mg QD	-1.03
600mg bid	-1.66

TOXICITY AND ADVERSE EVENTS

In healthy volunteers, oral doses of maraviroc to 900mg was found to be well tolerated³⁴. The common adverse effect reported with maraviroc includes nausea, dizziness, headache, gingivitis, and asthenia^{11, 22}. But at a 600mg dose or above, orthostatic hypotension occurred more frequently³⁵. The safety profile of placebo and maraviroc treatment groups has no difference in a trial with nausea, headache, fatigue, and diarrhoea being most frequent in all groups. A slightly higher chance of drowsiness and respiratory infections was accounted in the maraviroc treated groups^{36, 37}.

The 48 weeks phase II trial of vicriviroc showed overall good tolerability. No significant differences in adverse effects were seen between the different treatments of vicriviroc (5mg, 10mg, and 15mg) with placebo. No prolongation of QT interval was reported.³⁸

MALIGNANCIES

In 2006, the ACTG 5211 trial amongst antiretroviral therapy-treated adults with the R5 tropic virus who received 10-15mg QD ritonavir-boosted vicriviroc was unblinded because of the unexpected production of malignant lymphomas³⁹. In patients, randomized in a clinical trial of vicriviroc fatalities occurred in 6 patients with maraviroc and two patients with placebo, from which one had been exposed to vicriviroc treatment for three months. From 6 subjects of vicriviroc group, one was diagnosed with gastric adenoma and one with human papillomavirus-related cell carcinoma, two developed non-Hodgkin lymphoma, and two developed m. Hodgkin (1 had a history of treated Hodgkin disease)²⁸. The associations of occurrence of malignancies with vicriviroc treatment remain uncertain but appear to be not drug-related. The data that was available recently through ACTG study showed that there was no further development of malignancies. There is a need for further development to follow up this possible relation of vicriviroc use and malignancies. The data obtained from MOTIVATE 1 and 2 showed that there was no significant difference in the production of malignancies between maraviroc treated patients and placebo groups³⁵.

PHARMACOKINETICS OF CCR5 INHIBITORS

The pharmacokinetic study of HIV-1 patients revealed that maraviroc is absorbed rapidly with a T_{max} (time to maximum concentration) between 1-4 hours postdose. The plasma half-life ($t_{1/2}$) is from 16-23 hours and is dose dependent^{22, 34}. In the presence of food, vicriviroc is absorbed rapidly with T_{max} of approximately 2-3 hours. The plasma $t_{1/2}$ of vicriviroc is 28-32 hours; this data supports that the dose should be once daily^{25, 40}. A phase I trial in 24- patients with R5 tropic virus revealed that the steady-state concentration of maraviroc was achieved in 7 days and a fastedstate, the plasma concentration lowered up to 50%. The antiviral effect of maraviroc with dosing of the 150mg bid was found to be independent of food intake and reduces the viral load 1.45 \log_{10} copies/ml and 1.34 \log_{10} copies/ml for fasted and fed condition respectively. The study showed that there was no significant effect of food on vicriviroc pharmacokinetic profile. The vicriviroc can be administered with or without food⁴¹.

DRUG INTERACTION

The vicriviroc and maraviroc both are primarily metabolized by CYP3A4, an enzyme that is a member of cytochrome P450 system. When vicriviroc and maraviroc are co-administered with potent CYP3A4 inducer, the drug levels may decrease, and the drug levels may increase when these are co administered with potent CYP3A4 inhibitor. Therefore the drug-drug interactions can be possible especially with a protease

inhibitor. Dose of maraviroc reduces up to 50% in presence of protease inhibitor. Consequently, there is a recommendation for potent CYP3A4 inhibitor. An exception is with tipranavir which does not lead to any substantial changes, in maraviroc exposure in healthy participants⁴². When protease inhibitor is absent the maraviroc is given with rifampin, the dose of maraviroc has to be doubled⁴³. Maraviroc and Vicriviroc shows no significant inhibitory effects on any CYP450 enzyme, by making it unlikely that they can alter the metabolism of those drugs which are metabolized by cytochrome 450^{43, 44}. Pharmacokinetics studies on healthy volunteers showed that maraviroc does not affect the pK of NRTIs Zidovudine(AZT), Lamivudine (3TC) and Tenofovir(TDF). Metabolism characteristics of the vicriviroc are same to maraviroc. There are no clinically relevant effects on plasma exposure of vicriviroc, AZT, 3TC, and TDF when co-administered to healthy subjects^{45, 46}. When vicriviroc 10mg QD co-administered with 600mg efavirenz QD resulted in 81% decrease in AUC of vicriviroc⁴⁷. When vicriviroc is co-administered with LPV, the AUC increased by 4.2 fold. The currently reported dose of 100mg ritonavir bid + 15 mg vicriviroc leads to comparable vicriviroc levels as when 15mg is added to ritonavir-boosted PI. Therefore, in future vicriviroc will be added to the ritonavir-boosted Protease Inhibitor (PI) regimen without any dose adaptation⁴⁸.

Table 6: Summary of drug interactions

Drug Name	Effect on Maraviroc Exposure Levels	Effect on Dose of Maraviroc
Atazanavir	↑ (5 fold)	↓ (by 50%)
Darunavir	↑ (4 fold)	↓ (by 50%)
Efavirenz	↓ (by half)	Double (in the absence of PIs), ↓ (in the presence of a boosting dose of ritonavir)
Ketoconazole	↑ (5 fold)	↓ (by 50%)
Rifampin	↓ (by one third)	Double (in the absence of PIs)
Lopinavir	↑ (4 fold)	↓ (by 50%)
Tipranavir	No change	No dose modification
Ritonavir	↑ (by 2.6 fold)	↓ (by 50%)

CHALLENGES WITH MARAVIROC TREATMENT

There are approximately not more than 50% pretreated patients, infected with the R5 tropic virus and are possible subjects to maraviroc treatment and the remaining almost of 50% of patients with virologic failure owing to HAART resistance are not expected to benefit from maraviroc treatment. Before initiation of the therapy, it is essential to differentiate between R5 or R4 tropic virus. The first requirement of this assay is high-intensity viral load >500 copies per ml, and the major problem with this assay is the cost, i.e. \$1500-2000 per single test and the blood samples are shipped to the US for this assay⁴⁹.

CONCLUSION

Inside the mild of growing viral resistance in opposition to current antiretroviral drugs, the current improvement of this new class of ARV-therapy with a totally novel mechanism of action is beneficial. The CCR5-antagonists maraviroc and vicriviroc are energetic against current 3 drug-class-resistant R5-tropic HIV-1. The two substances have indicated powerful anti-retroviral action in pre-treated individuals with extreme HIV-disease. The trial results of maraviroc are promising. Vicriviroc was defied with more limitations on its way of clinical assessment. Nevertheless, after preliminary concerns associated with virologic breakthrough in low-dose treatment, sustained antiviral action of vicriviroc can also be suggested as long because it was boosted with ritonavir. Problems

concerning the presence of malignancies in patients treated with vicriviroc could not be affirmed in to boot follow-up assessment of this drug. The CCR5 antagonists are mostly metabolized by the manner of CYP3A4 framework. They don't repress or induce CYP450 at normal concentrations; however the co-administration of CYP3A4-inducers or –inhibitors may have influence on pharmacokinetics of vicriviroc and maraviroc. Consequently, when CCR5 antagonists are combined with different (ARV) drugs dose adjustments can be essential. Herewith two effective new antiretroviral devices are introduced in HIV work on, opening new treatment open doors for patients with multi-resistant strains of HIV. After the maraviroc approval, the first CCR5 inhibitor in the treatment of HIV-1 infection, trofile testing is required for

clinical use. The European concord group on clinical management of trofile testing gives a summary of obtainable published work, evidence-based proposals for the clinical utilization of trofile testing, and directions on uncertain components and improvements. Current information lend support to each the utilization of population genotyping and also the commercially out there increased sensitivity assay for establishing co-receptor response.

ACKNOWLEDGEMENT

We are highly thankful to Department of Pharmaceutical Sciences, Kumaun University Campus Bhimtal to provide support and help to this study. We are also thankful to Jyotsna Dwivedi and Mohammed Adil for help.

REFERENCES

- World Health Organization, the Public Health Response to Pretreatment HIV Drug Resistance, WHO Guidel. (2017).
- Carpenter C, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, *et al.* Antiretroviral Therapy for HIV Infection in 1998. American Medical Association. 1998; 280(1):78.
- Nichols WG, Steel HM, Adkison K, Curtis L, Millard J, Kabeya K, *et al.* Hepatotoxicity observed in clinical trials of aplaviroc. Antimicrobial agents and chemotherapy. 2008; 52(3):858-865.
- Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-5.
- Cohen C, DeJesus E, Mills A, *et al.* Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy [Abstract TUAB106]. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2007, Sydney, Australia.
- Shin N, Solomon K, Wang KH, *et al.* INCB9471 is a non-competitive small molecule antagonist of CCR5 [Abstract H-1032]. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
- Solomon K, Baribaud F, Shin N, *et al.* INCB9471 is a potent inhibitor of R5HIV-1 infection in vitro [Abstract H-1033]. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
- Jaysuriya H, Herath KB, Ondekya JG, Polishook JD, Gerald F, Drombrowski AW, *et al.* Isolation and structure of antagonists of chemokine receptor (CCR5). Journal of Natural Products 2004; 67:1036-1038.
- Baba M, Takashima K, Miyake H, *et al.* TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrobial Agents and Chemotherapy. 2005; 49(11):4584-4591.
- Samson M, Libert F, Doranz BJ, *et al.* Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382(6593):722-5
- Mayer H, van der Ryst E, Saag M, *et al.* Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract ThLB0215]. Presented at: XVI International AIDS Conference (IAC); 2006; Toronto [accessed on 12 June 2018] <https://quod.lib.umich.edu/c/cohen aids/5571095.0191.008/2?view=image&size=400>
- Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vézinet F, Clotet B, Luca AD, Dressler S, *et al.* European guidelines on the clinical management of HIV-1 tropism testing; Lancet Infect Dis 2011; 11:394-407
- Tremblay C, Hardy I, Lalonde R, *et al.* HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations. Can J Infect Dis Med Microbiol 2013; 24(4):202-208
- Hamy F, Vidal V, Hubert S, Klimkait T. Hybridization-based assay and replicative phenotyping as diagnostic platform for determination of coreceptor tropism [Abstract 60]. Presented at: 5th European HIV Drug Resistance Workshop; 2007; Monte Carlo.
- Van Baelen K, Vandenbroucke I, Rondelez E, Van Eygen V, Vermeiren H, Stuyver L. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods. 2007; 146:61-73
- Isaka Y, Sato A, Miki S, *et al.* Small amino acid changes in the V3 loop of HIV type 2 determines the coreceptor usage for CXCR4 and CCR5. Virology. 1999; 264:237-43.
- Seclen E, Poveda E, Garrido C, *et al.* High sensitivity to detect X4 variants using specific genotypic tools in antiretroviral-experienced HIV patients suitable to CCR5 antagonists therapy. J Antimicrob Chemother. 2010; 65:1486-92
- Briggs D, Tuttle D, Sleasman J, *et al.* Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2000; 14:2937-9
- Delobel P, Nugere M, Cazabat M, *et al.* Population-based sequencing of the V3 region of env for predicting the coreceptor usage of HIV type 1 quasispecies. J Clin Microbiol. 2007; 45:1572-80
- Hoffman N, Seillier-Moisewitsch F, Anh J, *et al.* Variability in the HIV type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol. 2002; 76:3852-64
- Sierra S, Kaiser R, Thielen A, *et al.* Genotypic coreceptor analysis. Eur J Med Res. 2007; 12:453-62
- Fatkenheuer G, Pozniak AL, Johnson MA, *et al.* Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11(11):1170-2
- Profit L. Maraviroc: the evidence for its potential in the management of HIV. Core Evidence 2007; 2(1):1-14
- Schürmann D, Rouzier R, Nourgarede R. SCH D: Antiviral activity of a CCR5 receptor antagonist [Abstract 140LB]. Presented at: 11th CROI; 2004; San Francisco.
- Schurmann D, Pechardscheck C, Rouzier R, *et al.* SCH 417690: antiviral activity of a potent new CCR5 receptor antagonist [Abstract TuOa0205]. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005 July 24-27; Rio de Janeiro, Brazil.
- Greaves W, Landovitz R, Fatkenheuer G *et al.* Late virologic breakthrough in treatment-naïve patients on a regimen of

- combivir plus vicriviroc [Abstract 161LB]. Presented at: XIII CROI; 2006; Denver.
27. Gulick R, Su Z, Flexner C, *et al.* ACTG 5211: phase 2 study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects [Abstract ThLB0217]. Presented at: XVI IAC; 2006; Toronto.
 28. Gulick R, Su Z, Flexner C *et al.* Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1–Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. *J Infect Dis* 2007; 196(2):304-12
 29. Tremblay CL, Giguel F, Kollmann C, *et al.* Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. *Antimicrob Agents Chemother* 2002; 46:1336–9.
 30. Gulick R, Su Z, Flexner C *et al.* ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results [Abstract TUAB102]. Presented at: 4th IAS Conference; 2007.
 31. Shah HR., Savjani JK. Recent updates for designing CCR5 antagonists as anti-retroviral agents. *European Journal of Medicinal Chemistry* 2018, 147:115-129.
 32. Lalezari J, Thompson M, Kumar P, *et al.* Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. *AIDS* 2005, 19(14): 1443–48
 33. Crabb C. GlaxoSmithKline ends aplaviroc trials. *AIDS* 2006, 20: 641
 34. Abel SE, VanderRyst GJ, Muirhead M, Rosario A, Edgington G, Weissgerber. Pharmacokinetics of Single and Multiple Oral Doses of UK-427,857-A Novel CCR5 Antagonist in Healthy Volunteers [Abstract 547]. Presented at: 10th CROI; February 2003; Boston, USA.
 35. McHale M., *et al.* Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857) [Abstract TuOa0204]. Presented at: The 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005.
 36. Lalezari J, Goodrich J, DeJesus E *et al.* Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced Patients Infected with CCR5tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and Canada [Abstract 104bLB]. Presented at: 14th CROI; 2007; Los Angeles.
 37. Nelson M, Fatkenheuer G, Kounourina I *et al.* Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results [Abstract 104aLB]. Presented at: 14th CROI; 2007; Los Angeles.
 38. Carl J, Lenz C, Rgen J, Rockstroh K. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges. *Expert Opin. Drug Metab. Toxicol.* 2010; 6(9):1139-1150
 39. Schering-Plough provides update on phase II study of vicriviroc: study continues in HIV treatment experienced patients (press release). Schering-Plough Corp, March 3, 2006
 40. Strizki JM, Tremblay C, Xu S, *et al.* Discovery and characterization of vicriviroc (SCH 417690), a R5 antagonist with potent activity against human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 2005; 49:4911-9
 41. Keung A, Sansone A, Caceres M, Kraan M, Gaillac B. Effect of Food on Bioavailability of SCH 417690 in Healthy Volunteers [abstract A-1200]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington.
 42. Abel S, *et al.* Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers [abstract LBPE4.3/15]. Presented at: 10th European AIDS Conference; November 17-20, 2005; Dublin.
 43. Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug-drug interaction data for maraviroc (UK427,857). Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy [Abstract 76]. April 28-30, 2005; Quebec City, Canada.
 44. Muirhead G, Pozniak A, Gazzard B, Nelson M, Moyle G, Ridgway C, Taylor-Worth R, Russell D. A Novel Probe Drug Interaction Study to Investigate the Effect of Selected ARV Combinations on the Pharmacokinetics of a Single Oral Dose of UK-427,857 in HIV⁺ Subjects [Abstract 663]. Presented at: 12th Retroconference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, USA.
 45. Sansone A, Guillaume M, Kraan M, Keung A, Caceres M, Boutros T. The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine [Abstract 84]. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Canada.
 46. Sansone A, Guillaume M, Kraan M, Soni P, Keung A, Boutros T. Pharmacokinetics of SCH 417690 administered alone and in combination with tenofovir [Abstract 85]. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Canada.
 47. Saltzman M, Rosenberg M, Kraan M, Keung A, Boutros T, Soni P, Sansone A. Pharmacokinetics of SCH417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers [Abstract TuPe3.1.B08]. Presented at: 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
 48. Sansone A, Keung A, Tetteh E, Weisbrot H, Martinho M, Lang S, *et al.* Pharmacokinetics of vicriviroc are not affected in combination with five different protease inhibitors boosted by ritonavir [Abstract 582]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver.
 49. Emmelkamp JM, Rockstroh JK. Maraviroc, risks and benefits: a review of the clinical literature. *Expert Opin. Drug Saf.* 2008; 7(5):559-569